<DOC>
	<DOCNO>NCT01667679</DOCNO>
	<brief_summary>This study conduct determine OPTINOSE SUMATRIPTAN deliver nasally ( nose ) use OPTINOSE SUMATRIPTAN DEVICE reduce pain associate migraine headache 30 minute use .</brief_summary>
	<brief_title>Efficacy Safety 20 mg Sumatriptan Powder Delivered Intranasally With Bi-directional Device Compared With 100 mg Sumatriptan Tablets Adults With Acute Migraine With Without Aura</brief_title>
	<detailed_description>The primary objective study compare proportion attack pain reduction ( defined decrease pain intensity least 1 point ) achieve 30 minute follow 20 mg OPTINOSE SUMATRIPTAN treatment 100 mg Sumatriptan Tablets</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Man woman , age 18 65 year , inclusive screening Have diagnosis episodic migraine , without aura accord InternationalClassification Headache Disorders ( 2nd Edition ) ( ICHD2 ) least 1 year prior screen Experiences 2 8 migraine attack per month past 12 month Women child bear potential must practice effective method birth control Women childbearing potential must negative urine pregnancy test screen visit negative urine pregnancy test randomization visit Demonstrate ability use bidirectional delivery device correctly Able willing read comprehend write instruction complete electronic diary information require protocol Must capable , opinion Investigator , provide informed consent participate study . Subjects ( legally acceptable representative , applicable ) must sign informed consent document indicate understand purpose procedure require study willing participate study Inability distinguish headache migraine Experiences headache kind frequency great equal 15 day per month History resistance sumatriptan , nonresponse 2 triptans , define subject respond adequate dose duration treatment Current use medication migraine prophylaxis stable ( dose adjustment ) 30 day prior screen Chronic opioid therapy ( &gt; 3 consecutive day 30 day prior screen ) Current treatment monoamine oxidase A ( MAOA ) inhibitor use within 4 week randomization Have hemiplegic basilar migraine History , symptoms sign ischemic cardiac , cerebrovascular peripheral vascular syndrome . Ischemic cardiac syndrome include , limited , angina pectoris type ( e.g. , stable angina effort , vasospastic form angina Prinzmetal variant ) , form myocardial infarction silent myocardial ischemia . Cerebrovascular syndrome include , limited , stroke type well transient ischemic attack . Peripheral vascular disease include , limited , ischemic bowel disease , Raynaud syndrome Uncontrolled hypertension ( screen systolic/diastolic blood pressure &gt; 140/95 mmHg ) Have severe hepatic impairment Have history epilepsy condition associate lowered seizure threshold History ( within 2 year ) drug alcohol abuse define Diagnostic Statistical Manual Mental Disorders 4th edition ( DSMIV ) criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headaches</keyword>
	<keyword>Sumatriptan</keyword>
</DOC>